金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01548 金斯瑞生物科技

未开盘 08-13 16:08:14

25.980

+1.120

+4.51%

最高26.720	最低24.600	成交量4,869万
今开24.880	昨收24.860	日振幅8.53%
总市值568.70亿	流通市值568.70亿	总股本21.89亿
成交额12.58亿	换手率2.22%	流通股本21.89亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":25.98,"timestamp":1786608494002,"preClose":24.86,"halted":0,"volume":48689473,"delay":0,"changeRate":0.0450522928399035,"floatShares":2189000000,"shares":2189000000,"eps":-1.928871868918325,"marketStatus":"未开盘","change":1.12,"latestTime":"08-13 16:08:14","open":24.88,"high":26.72,"low":24.6,"amount":1258399059,"amplitude":0.085278,"askPrice":25.98,"askSize":354000,"bidPrice":25.96,"bidSize":12000,"shortable":3,"etf":0,"ttmEps":-1.9292406930755228,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":0,"adr":0,"listingDate":1451404800000,"exchange":"SEHK","adjPreClose":24.86,"openAndCloseTimeList":[[1786584600000,1786593600000],[1786597200000,1786608000000]],"volumeRatio":0.7799617966111289,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548","defaultTab":"news","newsList":[{"id":"2659135038","title":"港股异动 | 金斯瑞生物科技(01548.HK)再涨超7% AI制药颠覆传统研发范式 创造全新研发需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135038","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659135038?lang=zh_cn&edition=full","pubTime":"2026-08-13 14:06","pubTimestamp":1786601216,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","01548","BK1574","01477","BK1191","BK1576","HK0000320223.HKD","HK0000306701.USD","HK0000306685.HKD","HK0000320264.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149590283","title":"异动解读｜金斯瑞生物科技盘中上涨3.7%，AI制药兑现叠加CARVYKTI销售高增及中期业绩审议在即持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1149590283","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149590283?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:35","pubTimestamp":1786588514,"startTime":"0","endTime":"0","summary":"8月13日，金斯瑞生物科技盘中上涨3.7%，报25.8港元，成交额4.05亿港元，延续近期强势表现。消息面上，多重利好持续催化：联营公司传奇生物CARVYKTI二季度销售额达6.57亿美元，同比增长49.4%，上半年销售额达12.54亿美元，同比增长55.1%；全球AI制药进入落地兑现期，美股Twist中报业绩超预期，AI相关订单同比翻倍增长，金斯瑞生命科学事业群收入达5.22亿美元，同比增长14.8%。此外，公司将于8月15日举行董事会会议审议中期业绩及股息安排，市场预期乐观。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109463102","title":"异动解读｜金斯瑞生物科技盘中上涨3.1%，AI制药兑现叠加CARVYKTI销售高增持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1109463102","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109463102?lang=zh_cn&edition=full","pubTime":"2026-08-12 09:41","pubTimestamp":1786498870,"startTime":"0","endTime":"0","summary":"8月12日，金斯瑞生物科技盘中上涨3.1%，报25.3港元，成交额8911.23万港元，延续近期强势表现。消息面上，多重利好持续催化：联营公司传奇生物已向美国SEC提交二季度财报，CARVYKTI二季度销售额达6.57亿美元，同比增长49.4%，上半年销售额达12.54亿美元，同比增长55.1%。同时，全球AI制药进入落地兑现期，美股Twist中报业绩超预期，AI相关订单同比翻倍增长，金斯瑞生命科学事业群收入达5.22亿美元，同比增长14.8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127652207","title":"金斯瑞生物科技(01548)：联营公司传奇生物已向美SEC提交截至2026年6月30日止第二季度财报","url":"https://stock-news.laohu8.com/highlight/detail?id=1127652207","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127652207?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:10","pubTimestamp":1786450245,"startTime":"0","endTime":"0","summary":"2026年8月11日，金斯瑞生物科技股份有限公司发布自愿性公告称，其联营公司传奇生物科技股份有限公司已于同日向美国证券交易委员会提交6-K表格，披露截至2026年6月30日止第二季度的财务业绩及近期业务亮点。传奇生物的股份以美国存托股份形式在纳斯达克全球精选市场上市。公告提醒，相关财务数据仅适用于传奇生物，并不代表金斯瑞生物科技本身的财务表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969219","title":"港股午评|恒生指数早盘跌0.63%    CRO概念继续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969219?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:00","pubTimestamp":1786420834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.63%，跌163点，报25773点；恒生科技指数跌1.27%。港股早盘成交1158亿港元。药明康德司法取得进展，有利于CXO公司在海外争取新的订单。再鼎医药涨超5%，Q2产品收入环比增长11%，花旗看好中国业务下半年企稳。津上机床中国涨超5%，电子与AI液冷两大领域在新订单占比约四成。黄金股普遍承压。油价走高加剧通胀上行担忧，美联储鹰派释放强硬信号。中国黄金国际跌2.5%；紫金矿业跌3.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1242518931.SGD","LU0737861772.HKD","LU0348767384.USD","02833","BK1190","06951","LU1808992512.USD","PONY","LU1720050803.USD","LU0456854461.SGD","LU2039709279.SGD","LU2097828474.EUR","09067","03032","LU0327786744.USD","BK1191","688234","LU0165289439.USD","LU0918141705.HKD","LU1504937902.USD","LU0149721374.USD","LU0561508036.HKD","ZLAB","LU0868486357.SGD","LU0370786039.SGD","HSI","LU0634319403.HKD","07300","LU0043850808.USD","LU0082770016.USD","BK1576","LU0307460666.USD","LU0588546209.SGD","LU0828238088.HKD","LU0871576103.HKD","HK0000306701.USD","LU0287142896.SGD","LU1769817096.USD","LU2097828557.USD","LU0061477393.USD","LU0173614495.USD","LU1481107354.HKD","02026","03417","LU0106252389.USD","01651","LU0211977185.USD","LU0348825331.USD","SG9999003461.SGD","688062","LU0140636845.USD","LU0540923850.HKD","BK1583","03037","LU0329678337.USD","06616","513600","LU1988902786.USD","BK1198","BK1161","BK1141","LU1188198961.HKD","ZIJMY","LU0326950275.SGD","BK1129","09688","LU1303224171.USD","BK1587","LU0048580855.USD","SG9999002463.SGD","83115","03088","HK0000306685.HKD","02899","LU1794554557.SGD","03033","01541","LU0244354667.USD","LU0431992006.USD","LU2488822045.USD","03423","BK1544","LU0417516738.SGD","LU0737861699.HKD","LU1961090484.USD","BK1592","01548","02837","07500","LU0164880469.USD","LU0417516902.SGD","300408","LU2097828714.EUR","06821","HK0000320223.HKD","SG9999004220.SGD","03759","LU0328353924.USD","LU0266512127.USD","BK1505","LU1105468828.SGD","LU2264538146.SGD","LU0049853897.USD","LU0918141887.USD","LU0345780521.USD","LU2460026573.USD","LU0828237940.HKD","LU0345780281.USD","LU0531971595.HKD","LU0348735423.USD","07200","LU1251922891.USD","02631","LU0329678170.USD","LU1064131342.USD","LU0082770016.SGD","BK1169","SG9999001093.SGD","JINFF","LU0979878070.USD","LU1282648689.USD","LU0181495838.USD","LU3063872942.SGD","HSTECH","IE0032431581.USD","LU0266512473.USD","LU2399975544.HKD","LU0886674414.USD","LU1224709979.USD","LU2177674079.SGD","LU0164865239.USD","LU0572944931.SGD","LU0096374516.USD","02800","HHImain","09088","601899","BK1594","BK1170","002821","LU0274383008.USD","LU0348814723.USD","BK1574","LU2097828631.EUR","BK1588","03067","LU0269904917.USD","82800","LU0469268626.HKD","LU0463099449.HKD","MCHmain","LU1770034418.SGD","LU0620787316.HKD","LU0348816934.USD","LU0348766576.USD","03115","LU0828237510.HKD","BK1183","LU0797268264.HKD","09115","LU0228659784.USD","LU0039217434.USD","LU1769817179.HKD","03419","LU2226246903.HKD","LU0278937759.USD","02493","300759","LU1242518857.USD","LU1719994722.HKD","02099","07226","LU0106959298.USD","LU1831875114.USD","LU2097828805.USD","LU1048596156.SGD","LU0348827113.USD","LU0821914370.USD","LU0164939612.USD","LU2008162690.USD","HK0000320264.USD","BK1109","LU0509642566.USD","07552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969611","title":"港股异动 | 金斯瑞生物科技(01548)涨近9% 海外Twist已获订单验证 AI需求已开始贡献业务增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969611","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969611?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:36","pubTimestamp":1786419380,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技涨近9%，截至发稿，涨8.94%，报26.32港元，成交额8.27亿港元。中邮证券指，AI制药持续进展，TWST高增验证DBTL闭环，关注产业链成长机遇。国联民生证券认为，金斯瑞从基因合成龙头向“基因至蛋白”一体化验证平台延伸，AI需求已开始贡献业务增量。AI驱动药物开发及多抗体药物开发需求增长，带动基因至蛋白业务快速成长；2025年生命科学事业群收入5.22亿美元，同比增长14.8%，同时持续扩大自动化、数字化生产能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4585","CHAT","HK0000306685.HKD","BK1576","AGIX","HK0000306701.USD","AIPO","BK4588","ARTY","KCAI","HK0000320223.HKD","BK1141","QTOC","VTHR","01548","VXUS","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1521","LU0072913022.USD","BK1588","159992","LU0315179316.USD","01093","03692","LU0326950275.SGD","LNGR","IE00B543WZ88.USD","KURE","01548","LU1226288170.HKD","LU2125910500.SGD","IE00B5MMRT66.SGD","LU0880133367.SGD","HK0000320223.HKD","06855","LU1152091168.USD","MEDX","LU1813983027.USD","LU2328871848.SGD","HK0000306685.HKD","LU1226287792.SGD","BK1576","02228","06978","BK1161","02359","BK1515","IE00BZ08YT58.USD","LU1993786604.SGD","LU1303224171.USD","BK1583","09969","BK1617","06160","LU2242644610.SGD","BK1500","02268","02410","IE00B031HY20.USD","LU1951186391.HKD","LU2488822045.USD","LU1226287875.USD","IBBQ","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140580353","title":"异动解读 | AI制药兑现叠加CARVYKTI销售高增，金斯瑞生物科技盘中大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140580353","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140580353?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:00","pubTimestamp":1786413630,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中股价大涨5.05%，引发市场关注。一方面，全球AI制药进入落地兑现期，美股Twist中报业绩超预期，AI相关订单同比翻倍增长，带动市场对AI驱动药物开发需求的关注。金斯瑞生命科学事业群覆盖DNA合成、蛋白生产、抗体开发及功能验证，AI驱动需求增长带动其基因至蛋白业务快速成长，生命科学事业群收入达5.22亿美元，同比增长14.8%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117454442","title":"异动解读｜金斯瑞生物科技盘中上涨3.23%，AI制药兑现期叠加CARVYKTI销售高增持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1117454442","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117454442?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:47","pubTimestamp":1786412834,"startTime":"0","endTime":"0","summary":"8月11日，金斯瑞生物科技盘中上涨3.23%，报24.94港元，成交额1.53亿港元，延续近日强势表现。消息面上，多重利好持续催化：一方面，全球AI制药进入落地兑现期，美股Twist中报业绩超预期，AI相关订单同比翻倍增长。金斯瑞生命科学事业群覆盖DNA合成、蛋白生产、抗体开发及功能验证，AI驱动药物开发需求增长带动基因至蛋白业务快速成长，生命科学事业群收入5.22亿美元，同比增长14.8%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933421","title":"资金动向｜北水加仓MINIMAX超10亿港元，中芯国际遭抛售4.5亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933421","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658933421?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:05","pubTimestamp":1786359956,"startTime":"0","endTime":"0","summary":"跟踪南向资金最新动态","market":"sh","thumbnail":"https://img3.gelonghui.com/35d7c-572a3f6c-6557-4e39-aae0-20705ea0eb8c.jpg?guru_height=852&guru_width=1280&guru_size=135719","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/35d7c-572a3f6c-6557-4e39-aae0-20705ea0eb8c.jpg?guru_height=852&guru_width=1280&guru_size=135719"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5992970","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU1282649067.USD","688981","LU0314109678.HKD","BK1163","LU2929501877.USD","LU1808992512.USD","LU1282649141.HKD","LU0211977185.USD","LU0307460666.USD","LU0274383008.USD","FPA","HK0000320223.HKD","LU2039709279.SGD","BK1610","LU1282649810.SGD","KBDCY","LU1813983027.USD","00100","BK1141","BK1526","MCHS","LU0488056044.USD","LU0384037296.USD","BK1117","LU1328277881.USD","BK1576","BK1607","HK0000306685.HKD","01548","LU2351347302.SGD","BK1170","01888","00981","LU0164880469.USD","LU1211504680.USD","LU2187417386.USD","LU0149721374.USD","SG9999004220.SGD","LU0588546209.SGD","BK1506","LU1481107354.HKD","HK0000320264.USD","HK0000306701.USD","BK1614","LU0648948544.HKD","00148","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658604503","title":"金斯瑞生物科技盘中涨超8% 全球AI制药落地进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2658604503","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658604503?lang=zh_cn&edition=full","pubTime":"2026-08-10 11:26","pubTimestamp":1786332360,"startTime":"0","endTime":"0","summary":"全球AI制药落地进入兑现期。美股Twist中报业绩超预期，AI相关订单同比翻倍增长，全年营收指引上调至4.56-4.57亿美元。据悉，金斯瑞生命科学事业群覆盖DNA合成、蛋白生产、抗体开发及功能验证，可以将AI生成序列进一步转化为实体蛋白及实验数据。AI驱动药物开发及多抗体药物开发需求增长，带动基因至蛋白业务快速成长；2025年生命科学事业群收入5.22亿美元，同比增长14.8%，同时持续扩大自动化、数字化生产能力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-10/doc-inimuzxp1267880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["QTOC","01548","BK1141","ARTY","BK1574","01477","BK1191","BK1576","AGIX","CHAT","HK0000306701.USD","HK0000306685.HKD","HK0000320223.HKD","VTHR","AIPO","HK0000320264.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658015036","title":"港股异动 | 金斯瑞生物科技(01548)涨超8% AIDD放大实验验证需求 机构看好“卖水人”逻辑强化","url":"https://stock-news.laohu8.com/highlight/detail?id=2658015036","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658015036?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:31","pubTimestamp":1786329118,"startTime":"0","endTime":"0","summary":"消息面上，全球AI制药落地进入兑现期。美股Twist中报业绩超预期，AI相关订单同比翻倍增长，全年营收指引上调至4.56-4.57亿美元。据悉，金斯瑞生命科学事业群覆盖DNA合成、蛋白生产、抗体开发及功能验证，可以将AI生成序列进一步转化为实体蛋白及实验数据。AI驱动药物开发及多抗体药物开发需求增长，带动基因至蛋白业务快速成长；2025年生命科学事业群收入5.22亿美元，同比增长14.8%，同时持续扩大自动化、数字化生产能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HK0000320264.USD","KCAI","HK0000306701.USD","BK1576","BK1141","HK0000306685.HKD","01548","HK0000320223.HKD","VXUS","BK1583","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658609113","title":"医药外包概念股集体扬升 药明生物（02269）涨4.36% 机构指行业景气度上行信号明确","url":"https://stock-news.laohu8.com/highlight/detail?id=2658609113","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658609113?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:58","pubTimestamp":1786327110,"startTime":"0","endTime":"0","summary":"消息面上，国金证券发布研报指，CXO行业已完整经历一轮产业周期，当下行业景气度上行信号明确。目前，随着外部压力缓释、全球投融资回暖，国内BD持续升温，行业已进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987777","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127","BK1141","HK0000320264.USD","KURE","LU0307460666.USD","01521","LU0348767384.USD","LU0320764599.SGD","BK1515","LU0043850808.USD","LU0417516738.SGD","LU0819121731.USD","02269","09939","BK1574","LU0052750758.USD","01548","LU0140636845.USD","06821","IE00B0JY6N72.USD","LU0588546209.SGD","LU1880383366.USD","BK1521","LU0051755006.USD","LU3063872942.SGD","159938","LU2242644610.SGD","LU0516422366.SGD","BK1589","LU0456827905.SGD","LU2125910500.SGD","BK1161","LU0979878070.USD","LU1242518857.USD","SG9999002562.SGD","01873","LU1046422090.SGD","LU0823426308.USD","HK0000306701.USD","LU0181495838.USD","BK1191","LU0516423174.USD","LU0823426480.USD","LU2039709279.SGD","LU1720050803.USD","LU1242518931.SGD","LU0572944931.SGD","BK1576","02359","LU0708995583.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165487511","title":"异动解读 | 金斯瑞生物科技盘中大涨6.61%，CARVYKTI销售强劲及业绩预期提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1165487511","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165487511?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:34","pubTimestamp":1786325673,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中股价大涨6.61%，引发市场关注。消息面上，公司联营公司传奇生物近日公布CARVYKTI二季度销售额达6.57亿美元，同比增长49.4%，上半年销售额达12.54亿美元，同比增长55.1%，销售增长势头强劲，显著提振了投资者信心。同时，金斯瑞生物科技即将举行董事会会议审议中期业绩及股息安排，市场对其中期业绩抱有乐观预期，进一步催化了股价上涨。此外，CXO板块近期整体表现强势，行业情绪升温也为股价提供了支撑。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194216573","title":"异动解读｜金斯瑞生物科技盘中上涨5.83%，CARVYKTI销售高增叠加中期业绩审议在即持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1194216573","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194216573?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:31","pubTimestamp":1786325509,"startTime":"0","endTime":"0","summary":"8月10日，金斯瑞生物科技盘中上涨5.83%，报24.22港元，成交额1.88亿港元，延续近期强势表现。消息面上，公司联营公司传奇生物二季度CARVYKTI销售额达6.57亿美元，同比增长49.4%，上半年销售额达12.54亿美元，同比增长55.1%。同时公司将于8月15日举行董事会会议审议中期业绩及股息安排，业绩预期乐观。此外，CXO板块近期整体走强，药明康德上半年扣非净利润同比增长约89%带动行业情绪升温，多重利好叠加推动股价持续走高。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134857640","title":"异动解读｜金斯瑞生物科技盘中上涨6.17%，CARVYKTI销售高增叠加中期业绩审议在即持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1134857640","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134857640?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:05","pubTimestamp":1786079126,"startTime":"0","endTime":"0","summary":"8月7日，金斯瑞生物科技盘中上涨6.17%，报21.0港元，成交额7.76亿港元，延续近期强势表现。消息面上，公司联营公司传奇生物二季度CARVYKTI销售额达6.57亿美元，同比增长49.4%，上半年销售额达12.54亿美元，同比增长55.1%。同时公司将于8月15日举行董事会会议审议中期业绩及股息安排，业绩预期乐观。此外，CXO板块近日整体走强，药明康德上半年扣非净利润同比增长约89%带动行业情绪升温，多重利好叠加推动股价持续走高。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"金斯瑞生物科技盘中上涨6.17%，CARVYKTI销售高增叠加中期业绩审议在即持续提振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657503494","title":"港股异动 | 金斯瑞生物科技(01548)再涨超5% 本月中旬将发业绩 上半年CARVYKTI销售同比大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2657503494","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657503494?lang=zh_cn&edition=full","pubTime":"2026-08-06 10:16","pubTimestamp":1785982595,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)再涨超5%，截至发稿，涨3.95%，报19.49港元，成交额2.87亿港元。消息面上，金斯瑞生物科技拟于8月15日举行董事会会议以批准中期业绩。公司此前公告称，第二季度，传奇生物CARVYKTI销售额达6.57亿美元，同比增长49.4%，环比增长10%。上半年销售额达12.54亿美元，同比增长55.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548","BK4585","BK1583","HK0000306685.HKD","HK0000306701.USD","VXUS","HK0000320264.USD","HK0000320223.HKD","BK1141","BK1576","KCAI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139451445","title":"异动解读｜金斯瑞生物科技盘中上涨5.07%，CARVYKTI二季度销售强劲叠加中期业绩审议在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1139451445","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139451445?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:51","pubTimestamp":1785981079,"startTime":"0","endTime":"0","summary":"8月6日，金斯瑞生物科技盘中上涨5.07%，报19.73港元，成交额2.05亿港元。消息面上，公司联营公司传奇生物披露CARVYKTI于截至6月30日止季度产生贸易销售净额约6.57亿美元，同比增长近五成，延续强劲增长态势。此外，CXO板块近日整体走强，药明康德上半年营收同比增长约39%、扣非净利润同比增长约89%的亮眼业绩带动板块情绪持续升温，金斯瑞生物科技受益于行业共振与自身基本面利好叠加。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金斯瑞生物科技盘中上涨5.07%，CARVYKTI二季度销售强劲叠加中期业绩审议在即","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127205349","title":"金斯瑞生物科技（01548）将于8月15日审议2026年中期业绩及股息安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1127205349","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127205349?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:43","pubTimestamp":1785919414,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技股份有限公司（01548）8月5日公告称，董事会会议计划于2026年8月15日（星期六）在美国举行，届时将审议并批准集团及其附属公司截至2026年6月30日止六个月的中期业绩及其发布，并考虑派发中期股息（如有）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175911616","title":"金斯瑞生物科技更新7月股份变动月报表，新增284,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1175911616","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175911616?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:31","pubTimestamp":1785918677,"startTime":"0","endTime":"0","summary":"2026年8月5日，金斯瑞生物科技股份有限公司公布截至2026年7月31日止月份的证券变动月报表。公告显示，公司法定股本本月无变化，维持在5,000,000,000股普通股，面值每股0.001美元，注册股本总额仍为5,000,000美元。截至2026年7月31日，金斯瑞生物科技已发行股份从上月末的2,188,547,343股增至2,188,831,343股，较上月份增加284,000股。本月股本变动主要来自于首次公开发售后股份期权计划的行权，相关新增股份数为284,000股，合计募集资金金额为992,704港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genscript.com","stockEarnings":[{"period":"1week","weight":0.3134},{"period":"1month","weight":0.8193},{"period":"3month","weight":0.8478},{"period":"6month","weight":1.1578},{"period":"1year","weight":0.4695},{"period":"ytd","weight":1.0918}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务，旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株，提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.000341},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075475},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.060575},{"month":4,"riseRate":0.545455,"avgChangeRate":0.057883},{"month":5,"riseRate":0.454545,"avgChangeRate":0.061694},{"month":6,"riseRate":0.545455,"avgChangeRate":0.030877},{"month":7,"riseRate":0.636364,"avgChangeRate":0.112261},{"month":8,"riseRate":0.454545,"avgChangeRate":0.131925},{"month":9,"riseRate":0.4,"avgChangeRate":-0.071937},{"month":10,"riseRate":0.6,"avgChangeRate":0.095918},{"month":11,"riseRate":0.6,"avgChangeRate":0.045101},{"month":12,"riseRate":0.3,"avgChangeRate":0.042047}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}